$BTAX
Biostax Corp. Stock $btax

$btax Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223011692 Filed on April 10, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$207.5K	$254.7K	$1.149M
YoY Change	14.26%	73.33%	96.29%
% of Gross Profit
Research & Development	$180.9K	$14.24K	$14.24K
YoY Change			-90.68%
% of Gross Profit
Depreciation & Amortization	$13.38K
YoY Change
% of Gross Profit
Operating Expenses	$401.8K	$268.9K	$1.163M
YoY Change		83.02%	57.62%
Operating Profit	-$401.8K		-$1.163M
YoY Change	121.25%		57.62%
Interest Expense	$14.30K	-$13.30K	$120.4K
YoY Change	-115.51%	-71.21%	-87.55%
% of Operating Profit
Other Income/Expense, Net	-$14.30K	$0.00	-$2.373M
YoY Change	-99.37%	-100.0%	-189.7%
Pretax Income	-$416.1K	-$278.9K	-$3.536M
YoY Change	-83.72%	36.32%	-198.61%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$416.1K	-$278.9K	-$3.536M
YoY Change	-83.72%	36.32%	-198.61%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.10
Diluted Earnings Per Share	$0.00	$0.00	-$0.10
COMMON SHARES
Basic Shares Outstanding	83.30M shares	82.76M shares	36.29M shares
Diluted Shares Outstanding	83.24M shares		36.29M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.99K	$150.5K	$150.5K
YoY Change	-95.62%	-95.21%	-95.21%
Cash & Equivalents	$34.99K	$150.5K
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$34.99K	$150.5K	$150.5K
YoY Change	-95.62%	-95.21%	-95.21%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.61K	$50.73K	$50.73K
YoY Change
Total Long-Term Assets	$761.7K	$813.2K	$813.2K
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$34.99K	$150.5K	$150.5K
Total Long-Term Assets	$761.7K	$813.2K	$813.2K
Total Assets	$796.7K	$963.7K	$963.7K
YoY Change	-0.3%	-69.3%	-69.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.300M	$1.300M	$1.300M
YoY Change	-40.1%	-40.48%	-40.48%
Accrued Expenses	$151.1K	$136.1K	$536.5K
YoY Change	-96.54%	-43.2%	-87.3%
Deferred Revenue
YoY Change
Short-Term Debt	$1.288M	$1.091M	$1.091M
YoY Change	-68.2%	-72.46%	-72.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.576M	$3.477M	$3.477M
YoY Change	-68.36%	-68.64%	-68.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.576M	$3.477M	$3.477M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.576M	$3.477M	$3.477M
YoY Change	-68.36%	-68.64%	-68.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$383.4M	-$383.0M
YoY Change		0.93%
Common Stock	$380.6M	$380.4M
YoY Change		2.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.780M	-$2.513M	-$2.513M
YoY Change
Total Liabilities & Shareholders Equity	$796.7K	$963.7K	$963.7K
YoY Change	-0.3%	-69.3%	-69.3%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$416.1K	-$278.9K	-$3.536M
YoY Change	-83.72%	36.32%	-198.61%
Depreciation, Depletion And Amortization	$13.38K
YoY Change
Cash From Operating Activities	-$265.5K	$415.1K	-$581.8K
YoY Change	365.79%	-3839.19%	151.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$500.0K	-$500.0K
YoY Change
Cash From Investing Activities		-$500.0K	-$500.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$150.0K	50.00K	$738.4K
YoY Change		-89.49%	3.19%
NET CHANGE
Cash From Operating Activities	-$265.5K	415.1K	-$581.8K
Cash From Investing Activities		-500.0K	-$500.0K
Cash From Financing Activities	$150.0K	50.00K	$738.4K
Net Change In Cash	-$115.5K	-34.95K	-$343.4K
YoY Change	102.63%	-107.52%
FREE CASH FLOW
Cash From Operating Activities	-$265.5K	$415.1K	-$581.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001559356
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi		usd
CY2021Q4	IMUN	Patents And Licenses PatentsAndLicenses		usd
CY2021Q4	us-gaap	Deposits Assets DepositsAssets		usd
CY2022Q4	IMUN	Undocumented Investor Advances Current UndocumentedInvestorAdvancesCurrent		usd
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent		usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2021	us-gaap	Gross Profit GrossProfit		usd
CY2021	IMUN	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense		usd
CY2022	IMUN	Receipt Of Common Shares ReceiptOfCommonShares		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	IMUN	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2021	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
CY2022	IMUN	Gain Recognized Upon Receipt Of Equity Securities GainRecognizedUponReceiptOfEquitySecurities		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
CY2021	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2021	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice
CY2021	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
CY2022	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
CY2022Q4	IMUN	Deferred Tax Assets Amortization Depreciation And Impairment DeferredTaxAssetsAmortizationDepreciationAndImpairment		usd
CY2021Q4	IMUN	Deferred Tax Assets Amortization Depreciation And Impairment DeferredTaxAssetsAmortizationDepreciationAndImpairment		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-54933
CY2022	dei	Entity Registrant Name EntityRegistrantName	IMMUNE THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3226705
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2431 Aloma Ave.
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 124
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Winter Park
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32792
CY2022	dei	City Area Code CityAreaCode	888
CY2022	dei	Local Phone Number LocalPhoneNumber	613-8802
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	IMUN
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	7600000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83295857	shares
CY2022	dei	Auditor Firm AuditorFirmId	76
CY2022	dei	Auditor Name AuditorName	Turner, Stone & Company, L.L.P
CY2022	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150491	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	493885	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2645000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	150491	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3138885	usd
CY2022Q4	IMUN	Patents And Licenses PatentsAndLicenses	762500	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	50728	usd
CY2022Q4	us-gaap	Assets Assets	963719	usd
CY2021Q4	us-gaap	Assets Assets	3138885	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1300366	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2184848	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3421176	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3070208	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	394736	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	891420	usd
CY2021Q4	IMUN	Undocumented Investor Advances Current UndocumentedInvestorAdvancesCurrent	715631	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	64455	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	564300	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	136057	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	239558	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	549079	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3477173	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11087141	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3477173	usd
CY2021Q4	us-gaap	Liabilities Liabilities	11087141	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83045857	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83045857	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	483714	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	483714	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8305	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	49	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380436432	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	371473810	usd
CY2022Q4	IMUN	Stock Issuances Due StockIssuancesDue	10303	usd
CY2021Q4	IMUN	Stock Issuances Due StockIssuancesDue	10303	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382968494	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-379432418	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	963719	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3138885	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1149257	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	585502	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14236	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	152667	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1163493	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	738169	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1163493	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-738169	usd
CY2022	IMUN	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense	3165151	usd
CY2022	us-gaap	Interest Expense InterestExpense	120403	usd
CY2021	us-gaap	Interest Expense InterestExpense	210919	usd
CY2021	IMUN	Receipt Of Common Shares ReceiptOfCommonShares	5761500	usd
CY2022	IMUN	Change In Market Value Of Common Shares ChangeInMarketValueOfCommonShares	2645000	usd
CY2021	IMUN	Change In Market Value Of Common Shares ChangeInMarketValueOfCommonShares	3116500	usd
CY2022	IMUN	Loss Gain On Settlement Of Obligations And Conversion Of Debt LossGainOnSettlementOfObligationsAndConversionOfDebt	-1166418	usd
CY2021	IMUN	Loss Gain On Settlement Of Obligations And Conversion Of Debt LossGainOnSettlementOfObligationsAndConversionOfDebt	711892	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1178230	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2372583	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4324203	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3536076	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3586034	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.43
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36290359	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	482826	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36290359	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9394164	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11666981	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	56480	usd
CY2021	IMUN	Adjustments To Additional Paid In Extinguishment Of Derivative Liability Upon Conversion Of Debt AdjustmentsToAdditionalPaidInExtinguishmentOfDerivativeLiabilityUponConversionOfDebt	76211	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3586034	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6283168	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	723324	usd
CY2022	IMUN	Adjustments To Additional Paid In Charge Resulting From Warrant Modification AdjustmentsToAdditionalPaidInChargeResultingFromWarrantModification	1605913	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	95973	usd
CY2022	IMUN	Stock Issued During Period Value Issued For Intangible Assets StockIssuedDuringPeriodValueIssuedForIntangibleAssets	262500	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3536076	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3536076	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3536076	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3586034	usd
CY2022	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement	3165151	usd
CY2021	IMUN	Gain Recognized Upon Receipt Of Equity Securities GainRecognizedUponReceiptOfEquitySecurities	5761500	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2645000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3116500	usd
CY2022	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	-1166418	usd
CY2021	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	711892	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1178230	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	34790	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
CY2022	IMUN	Increase Decrease In Deposit IncreaseDecreaseInDeposit	-50728	usd
CY2021	IMUN	Increase Decrease In Deposit IncreaseDecreaseInDeposit	200	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	388539	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	103752	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4620	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	24000	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	130229	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	176131	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-75321	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	18498	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	304736	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	360000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-581821	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-231717	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-500000	usd
CY2022	IMUN	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances	6369	usd
CY2021	IMUN	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances	715631	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	417058	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	315000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	738427	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	715631	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-343394	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	483914	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	493885	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9971	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150491	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	493885	usd
CY2022	IMUN	Reclassification To Notes Payable From Accrued Interest ReclassificationToNotesPayableFromAccruedInterest	7006492	usd
CY2021	IMUN	Reclassification To Notes Payable From Accrued Interest ReclassificationToNotesPayableFromAccruedInterest	243568	usd
CY2022	IMUN	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	95973	usd
CY2021	IMUN	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	56480	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	262500	usd
CY2022Q4	us-gaap	Cash Cash	150491	usd
CY2022Q4	IMUN	Working Capital WorkingCapital	3326682	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3536076	usd
CY2022	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	2645000	usd
CY2022	IMUN	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	36260359	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_z4guI0FK8IQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zDITvu0LLWM2">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zuvM94YBBgo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zCYxklONYN3c">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zjbn5lPBxPff" title="Cash at federal deposit">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	IMUN	Effect Of Warrants And Notes Payable Convertible Into Common Stock EffectOfWarrantsAndNotesPayableConvertibleIntoCommonStock	-3536076	usd
CY2022	IMUN	Weighted Average Number Of Diluted Share Outstanding WeightedAverageNumberOfDilutedShareOutstanding	36260359	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice	0.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	38495	shares
CY2022Q4	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	59.42
CY2022	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_842_eus-gaap--DerivativesReportingOfDerivativeActivity_znhmdh0VHcBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z7uYZC30UN22">Derivative Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 815, Fair Value Measurements requires bifurcation of certain embedded derivative instruments in certain debt or equity instruments, and measurement at their fair value for accounting purposes. A holder redemption feature embedded in the Company’s note payable requires bifurcation from its host instrument and is accounted for as a freestanding derivative. The Company held no derivative financial instruments at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	38495	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15218668	shares
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3536076	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3070208	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	64455	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	564300	usd
CY2022	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	-1166418	usd
CY2021	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	711892	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83045857	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	483714	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	38495	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	20081035	shares
CY2020Q4	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	4.22
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	23873	shares
CY2021	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice	144.78
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	20057162	shares
CY2021Q4	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	5.21
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	2293667	shares
CY2022	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice	205.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	17725000	shares
CY2022	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice	0.05
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	92490000	usd
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	2033
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	27,861,000 will be limited to 80% of taxable income but will not expire
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19423000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23281000	usd
CY2022Q4	IMUN	Deferred Tax Assets Temporary Difference DeferredTaxAssetsTemporaryDifference	893000	usd
CY2021Q4	IMUN	Deferred Tax Assets Temporary Difference DeferredTaxAssetsTemporaryDifference	21000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18530000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23302000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18530000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23302000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.172	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.114	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.253	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	11.423	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.215	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-11.747	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0	pure
CY2022Q4	us-gaap	Share Price SharePrice	0.05
CY2022	IMUN	Cash Payment Description CashPaymentDescription	In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“NAFDAC”) approval for JKB-122 in Africa for any indication, or the enrollment of the first patient in a Food and Drug Administration (“FDA”) trail for Crohn’s Disease, (iii) 250,000 shares of common stock of the Company within sixty (60) days of September 30, 2022, (iv) an annual payment of $100,000 each anniversary of the date of the agreement until the Company gains regulatory approval in Africa, (v) milestone payments (described below), and (vi) royalties on net sales. The 250,000 shares of common stock represent approximately 0.32% of the currently outstanding common stock of the Company.
CY2022	IMUN	Description For Monthly Interest For Payment DescriptionForMonthlyInterestForPayment	the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due
CY2022Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	100000	usd
CY2022	us-gaap	Debt Instrument Description DebtInstrumentDescription	The third note is for the principal amount of $200,000. Each of the three notes: (a) matures on July 19, 2023, with the Company having the option to extend the maturity date by six months (b) carries a six percent (6.00%) per annum simple interest rate; (c) provides that, if converted by the holder in accordance with its terms, the Company shall issue a number of shares of common stock in the Company to the holder of the note equal to (i) the principal amount of the note divided by (ii) $0.05, subject to certain equitable adjustments; and (d) requires the note holder to notify the Company in writing by 11:59 p.m. on July 22, 2022, the expiration of the conversion provision in each note; of its intent to exercise its conversion right. If converted into shares of common stock, each of the three notes prohibits the note holder, without the prior written consent of the Company, from selling, pledging, or otherwise transferring such shares for one year from their date of issuance, except that up to 5% of the shares may be sold, pledged, or otherwise transferred during three of every four calendar quarters during the 18-month period following the issuance date of the converted Note
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	200000	usd
CY2022	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-07-19
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0600	pure
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	200000	usd
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	2500000	shares
CY2022	IMUN	Non Convertible Mistake NonConvertibleMistake	100000	usd

Files In Submission

Name	View Source	Status
0001493152-23-011692-index-headers.html	Edgar Link	pending
0001493152-23-011692-index.html	Edgar Link	pending
0001493152-23-011692.txt	Edgar Link	pending
0001493152-23-011692-xbrl.zip	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-6_001.jpg	Edgar Link	pending
ex10-6_002.jpg	Edgar Link	pending
ex10-6_003.jpg	Edgar Link	pending
ex10-6_004.jpg	Edgar Link	pending
ex10-6_005.jpg	Edgar Link	pending
ex10-6_006.jpg	Edgar Link	pending
ex10-6_007.jpg	Edgar Link	pending
ex10-6_008.jpg	Edgar Link	pending
ex10-6_009.jpg	Edgar Link	pending
ex10-6_010.jpg	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-7_001.jpg	Edgar Link	pending
ex10-7_002.jpg	Edgar Link	pending
ex10-7_003.jpg	Edgar Link	pending
ex10-7_004.jpg	Edgar Link	pending
ex10-7_005.jpg	Edgar Link	pending
ex10-7_006.jpg	Edgar Link	pending
ex10-7_007.jpg	Edgar Link	pending
ex10-7_008.jpg	Edgar Link	pending
ex10-7_009.jpg	Edgar Link	pending
ex10-7_010.jpg	Edgar Link	pending
ex10-7_011.jpg	Edgar Link	pending
ex10-7_012.jpg	Edgar Link	pending
ex10-7_013.jpg	Edgar Link	pending
ex10-7_014.jpg	Edgar Link	pending
ex10-7_015.jpg	Edgar Link	pending
ex10-7_016.jpg	Edgar Link	pending
ex10-7_017.jpg	Edgar Link	pending
ex10-7_018.jpg	Edgar Link	pending
ex10-7_019.jpg	Edgar Link	pending
ex14-1.htm	Edgar Link	pending
ex14-1_001.jpg	Edgar Link	pending
ex14-1_002.jpg	Edgar Link	pending
ex14-1_003.jpg	Edgar Link	pending
ex14-1_004.jpg	Edgar Link	pending
ex14-1_005.jpg	Edgar Link	pending
ex14-1_006.jpg	Edgar Link	pending
ex14-1_007.jpg	Edgar Link	pending
ex14-1_008.jpg	Edgar Link	pending
ex14-1_009.jpg	Edgar Link	pending
ex14-1_010.jpg	Edgar Link	pending
ex14-1_011.jpg	Edgar Link	pending
ex14-1_012.jpg	Edgar Link	pending
ex14-1_013.jpg	Edgar Link	pending
ex14-1_014.jpg	Edgar Link	pending
ex14-1_015.jpg	Edgar Link	pending
ex14-1_016.jpg	Edgar Link	pending
ex14-1_017.jpg	Edgar Link	pending
ex14-1_018.jpg	Edgar Link	pending
ex14-1_019.jpg	Edgar Link	pending
ex14-1_020.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
fin_002.jpg	Edgar Link	pending
form10-k.htm	Edgar Link	pending
imun-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
imun-20221231_cal.xml	Edgar Link	unprocessable
imun-20221231_lab.xml	Edgar Link	unprocessable
imun-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
imun-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTAX
Biostax Corp. Stock $btax

2023 Q1 Form 10-K Financial Statement

#000149315223011692 Filed on April 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX Biostax Corp. Stock $btax

2023 Q1 Form 10-K Financial Statement

#000149315223011692 Filed on April 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX
Biostax Corp. Stock $btax